Target Name: ALDOA
NCBI ID: G226
Review Report on ALDOA Target / Biomarker Content of Review Report on ALDOA Target / Biomarker
ALDOA
Other Name(s): Aldolase A, fructose-bisphosphate | lung cancer antigen NY-LU-1 | aldolase A, fructose-bisphosphate | Aldolase A | epididymis secretory sperm binding protein Li 87p | uncharacterized LOC102723572 | ALDOA_HUMAN | GSD12 | Aldolase, fructose-bisphosphate A, transcript variant 6 | HEL-S-87p | Epididymis secretory sperm binding protein Li 87p | Fructose-1,6-bisphosphate triosephosphate-lyase | Fructose-bisphosphate aldolase A | Muscle-type aldolase | aldolase, fructose-bisphosphate A | fructose-1,6-bisphosphate triosephosphate-lyase | Fructose-bisphosphate aldolase A (isoform 1) | ALDOA variant 1 | ALDOA variant 6 | Fructose-bisphosphate aldolase A (isoform 2) | ALDA | Aldolase A, fructose-bisphosphate, transcript variant 1 | muscle-type aldolase | Lung cancer antigen NY-LU-1

ALDOA: Key Enzyme in Glucose Metabolism

ALDOA (Aldolase A, fructose-bisphosphate) is a protein that is expressed in most tissues of the body. It is a key enzyme in the glycolytic pathway, which is the primary pathway for the metabolism of glucose. ALDOA is responsible for breaking down the glucose molecule into two

Protein Name: Aldolase, Fructose-bisphosphate A

Functions: Catalyzes the reversible conversion of beta-D-fructose 1,6-bisphosphate (FBP) into two triose phosphate and plays a key role in glycolysis and gluconeogenesis (PubMed:14766013). In addition, may also function as scaffolding protein (By similarity)

The "ALDOA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALDOA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ALDOAP2 | ALDOB | ALDOC | ALG1 | ALG10 | ALG10B | ALG11 | ALG12 | ALG13 | ALG14 | ALG1L10P | ALG1L13P | ALG1L1P | ALG1L2 | ALG1L5P | ALG1L7P | ALG1L8P | ALG2 | ALG3 | ALG5 | ALG6 | ALG8 | ALG9 | ALK | ALKAL1 | ALKAL2 | Alkaline Phosphatase (ALP) | ALKBH1 | ALKBH2 | ALKBH3 | ALKBH4 | ALKBH5 | ALKBH6 | ALKBH7 | ALKBH8 | ALLC | ALMS1 | ALMS1-IT1 | ALMS1P1 | ALOX12 | ALOX12-AS1 | ALOX12B | ALOX12P2 | ALOX15 | ALOX15B | ALOX15P1 | ALOX15P2 | ALOX5 | ALOX5AP | ALOXE3 | ALPG | Alpha-2 Adrenergic receptors | alpha-6 beta-2 Nicotinic receptor | alpha-Adrenoceptor | alpha-Amylase | alpha-beta T Cell Receptor Complex (TCR) | Alpha-crystallin | alpha-Mannosidase | alpha-Secretase | alpha1-Adrenoceptor | ALPI | ALPK1 | ALPK2 | ALPK3 | ALPL | ALPP | ALS2 | ALS2CL | ALX1 | ALX3 | ALX4 | ALYREF | AMACR | AMBN | AMBP | AMBRA1 | AMD1 | AMD1P2 | AMDHD1 | AMDHD2 | AMELX | AMELY | AMER1 | AMER2 | AMER3 | AMFR | AMH | AMHR2 | AMIGO1 | AMIGO2 | AMIGO3 | Amine oxidase (copper containing) | Amino acid hydroxylase | Aminoacyl-tRNA Synthetase Complex | AMMECR1 | AMMECR1L | AMN | AMN1 | AMOT | AMOTL1